BioMarin Pharmaceutical: Compensatory Arrangements Of Certain Officers

The following excerpt is from the company's SEC filing.

On December 19, 2013, the Board of Directors (the “Board”) of BioMarin Pharmaceutical, Inc. (the “Company”) approved a promotion for Jeff Ajer to Executive Vice President, Chief Commercial Officer. In connection with his promotion, the Board approved an increase in his base salary to $425,000 per annum, to be effective in March 2014. Additionally, the Board approved an increase to his target cash bonus under the Company’s annual bonus program to 50% of base salary, which increase will be effective for his 2014 bonus, payable in the first quarter 2015.

The Board also approved the following adjustments to th e target bonuses payable under the Company’s annual bonus program for certain other executive officers. Each of these adjustments will be effective for the 2014 bonus, which is payable in 2015. The adjusted levels are as follows:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever BioMarin Pharmaceutical Inc. makes a similar move, sign up!

   Auto Refresh